Metraipolis › archive › dc_1b4ae4bc508a
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market — Europe PMC PMID:41217752
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41217752
- DOI
- 10.1001/jamanetworkopen.2025.42937
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T20:19:20.191Z
- SHA-256 of the archived text
feac0f6783852fcbe0572833ef7bc48051b8c04ad7525dcd19cab9d062652843- Stable URL of this page
https://metraipolis.com/documento/dc_1b4ae4bc508a
How to cite
Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market — Europe PMC PMID:41217752 — Europe PMC (en), https://europepmc.org/article/MED/41217752 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_1b4ae4bc508a (Metraipolis archive dc_1b4ae4bc508a, sha256 feac0f6783852fcbe0572833ef7bc48051b8c04ad7525dcd19cab9d062652843)
BibTeX
@misc{dc1b4ae4bc508a,
title = {Biologic Drug Prices in Medicare Part B After Entry of Biosimilars to the Market — Europe PMC PMID:41217752},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41217752},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_1b4ae4bc508a; sha256 feac0f6783852fcbe0572833ef7bc48051b8c04ad7525dcd19cab9d062652843},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41217752. Agents can read the archived copy with the MCP tool read_document.